NR1H4 and alcoholic fatty liver disease: A phase II proof-of-concept study in non-alcoholic steatohepatitis combined semaglutide with the FXR agonist cilofexor, and the acetyl-CoA carboxylase (ACC) inhibitor firsocostat [95].